Johnson & Johnson Outperforms Peers Despite Slower Revenue Growth
Over the past twelve months, Johnson & Johnson (JNJ) has outperformed several of its healthcare peers in stock returns despite slower revenue growth. JNJ's shares returned 58%, second best among six major health care companies, while Eli Lilly and others grew faster but delivered lower returns. The company’s performance is attributed to strong growth from key drugs like TREMFYA and DARZALEX, which offset declining sales of STELARA due to biosimilar competition. JNJ trades at a more attractive valuation compared to peers such as Lilly (LLY) and AbbVie (ABBV), with lower price-to-earnings ratios. The market appears to be betting on the company's future performance once STELARA’s declining sales no longer drag down overall revenue growth. However, challenges remain in its MedTech segment, which saw only modest growth and below-standard cardiovascular results. The upcoming third-quarter earnings report will provide a clearer picture of JNJ's momentum without calendar-driven boosts from an extra week in the 2026 fiscal year.
Tickers: $ABBV $JNJ $LLY $MDT $MRK $PFE
Topics: Eli Lilly healthcare sector Johnson & Johnson revenue growth stock returns